CONTROL OF CYTOMEGALOVIRUS RETINITIS USING SUSTAINED-RELEASE OF INTRAOCULAR GANCICLOVIR
CONTROL OF CYTOMEGALOVIRUS RETINITIS USING SUSTAINED-RELEASE OF INTRAOCULAR GANCICLOVIR
复制标题
DOI：
10.1001/archopht.1993.01090020077027
复制
发表时间：
1993-02-01
影响因子：
--
通讯作者：
ASHTON, P
中科院分区：
文献类型：
--
作者：
ANAND, R;NIGHTINGALE, SD;ASHTON, P
一种实验性玻璃体内缓释装置含有更昔洛韦用于治疗22例获得性免疫缺陷综合征相关的巨细胞病毒视网膜炎。排除了14只眼睛（5只未受累，9只有黄斑瘢痕和/或严重虚弱）。30眼接受了更昔洛韦眼内装置植入，并进行了前瞻性随访，从16至419天（中位数，125天）。30只眼中27只眼（90%）显示视网膜炎稳定。一旦装置中没有更昔洛韦，27只眼睛中的9只（33%）显示视网膜炎复发; 7只接受了更换装置，随后视网膜炎稳定。术后并发症包括玻璃体积血（n=1）、眼内炎（n=1）和进行性视网膜炎（n=2）。术后35 ~ 140天3眼（11%）发生晚期视网膜脱离。所有30只眼睛的生存分析显示视网膜炎进展的平均时间为19周（133天）。更昔洛韦眼内装置为治疗与获得性免疫缺陷综合征相关的巨细胞病毒性视网膜炎提供了一种有希望的替代方案。
An experimental intravitreal sustained-release device containing ganciclovir was used to treat 22 patients with acquired immunodeficiency syndrome-associated cytomegalovirus retinitis. Fourteen eyes were excluded (five not involved and nine with macular scarring and/or severe debility). Thirty eyes received the ganciclovir intraocular device implant and were prospectively followed up from 16 to 419 days (median, 125 days). Twenty-seven (90%) of 30 eyes showed stabilization of the retinitis. Nine (33%) of 27 eyes showed reactivation of the retinitis once the device was empty of ganciclovir; seven received a replacement device, with subsequent stabilization of the retinitis. Postoperative complications included vitreous hemorrhage (n=1), endophthalmitis (n=1), and progressive retinitis (n=2). Late retinal detachment was seen in three eyes (11%) at 35 to 140 days. Survival analysis of all 30 eyes revealed the mean time to progression of retinitis to be 19 weeks (133 days). The ganciclovir intraocular device offers a promising alternative for the treatment of cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.